TY - JOUR
T1 - Reclassifying Papillary, Oncocytic and Chromophobe Renal Tumours Based on the 5 th Who Classification 2022
AU - Shaikh, Nilofar
AU - Mathew, Mary
N1 - Publisher Copyright:
© 2024 The Author(s).
PY - 2024/5/1
Y1 - 2024/5/1
N2 - OBJECTIVE: The classification of renal tumors is expanding with the addition of new molecular entities in the 5th World Health Organization classification. Apart from this, the major updates in the definition of papillary renal cell carcinoma are that these tumors are no longer subtyped into type 1 and type 2. In oncocytic tumors, the new molecularly defined renal tumors, emerging and novel entities need to be considered in the diagnosis of oncocytic and chromophobe renal tumors. MATERIAL AND METHODS: This is a retrospective study to review and reclassify papillary, oncocytic, and chromophobe renal tumors based on the new WHO classification and correlate with clinical data, gross, microscopic features, and immunohistochemistry markers. RESULTS: A total of thirteen cases were reviewed and the tumor grade was changed for three out of four cases of papillary renal cell carcinoma and a single case was recategorized and graded. In nine cases of oncocytic and chromophobe renal tumors, the diagnoses were modified in 3 cases. CONCLUSION: Newly defined molecular renal tumors require advanced immunohistochemistry markers and molecular tests. This poses diagnostic challenges to pathologists practicing in low resource settings where molecular tests are not available.
AB - OBJECTIVE: The classification of renal tumors is expanding with the addition of new molecular entities in the 5th World Health Organization classification. Apart from this, the major updates in the definition of papillary renal cell carcinoma are that these tumors are no longer subtyped into type 1 and type 2. In oncocytic tumors, the new molecularly defined renal tumors, emerging and novel entities need to be considered in the diagnosis of oncocytic and chromophobe renal tumors. MATERIAL AND METHODS: This is a retrospective study to review and reclassify papillary, oncocytic, and chromophobe renal tumors based on the new WHO classification and correlate with clinical data, gross, microscopic features, and immunohistochemistry markers. RESULTS: A total of thirteen cases were reviewed and the tumor grade was changed for three out of four cases of papillary renal cell carcinoma and a single case was recategorized and graded. In nine cases of oncocytic and chromophobe renal tumors, the diagnoses were modified in 3 cases. CONCLUSION: Newly defined molecular renal tumors require advanced immunohistochemistry markers and molecular tests. This poses diagnostic challenges to pathologists practicing in low resource settings where molecular tests are not available.
UR - http://www.scopus.com/inward/record.url?scp=85193087788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85193087788&partnerID=8YFLogxK
U2 - 10.5146/tjpath.2024.13052
DO - 10.5146/tjpath.2024.13052
M3 - Article
C2 - 38265103
AN - SCOPUS:85193087788
SN - 1018-5615
VL - 40
SP - 122
EP - 127
JO - Turk Patoloji Dergisi
JF - Turk Patoloji Dergisi
IS - 2
ER -